159 related articles for article (PubMed ID: 24038152)
1. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study.
Engelke K; Nagase S; Fuerst T; Small M; Kuwayama T; Deacon S; Eastell R; Genant HK
J Bone Miner Res; 2014 Mar; 29(3):629-38. PubMed ID: 24038152
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study.
Eastell R; Nagase S; Ohyama M; Small M; Sawyer J; Boonen S; Spector T; Kuwayama T; Deacon S
J Bone Miner Res; 2011 Jun; 26(6):1303-12. PubMed ID: 21312264
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis.
Tanaka M; Hashimoto Y; Hasegawa C; Deacon S; Eastell R
BMC Musculoskelet Disord; 2017 Jun; 18(1):267. PubMed ID: 28629344
[TBL] [Abstract][Full Text] [Related]
4. Effects of 16-month treatment with the cathepsin K inhibitor ONO-5334 on bone markers, mineral density, strength and histomorphometry in ovariectomized cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Nakanishi Y; Tanaka M; Bruce M; Deacon S; Kawabata K
Bone; 2016 May; 86():43-52. PubMed ID: 26921823
[TBL] [Abstract][Full Text] [Related]
5. Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study.
Eastell R; Nagase S; Small M; Boonen S; Spector T; Ohyama M; Kuwayama T; Deacon S
J Bone Miner Res; 2014 Feb; 29(2):458-66. PubMed ID: 23873670
[TBL] [Abstract][Full Text] [Related]
6. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
Brixen K; Chapurlat R; Cheung AM; Keaveny TM; Fuerst T; Engelke K; Recker R; Dardzinski B; Verbruggen N; Ather S; Rosenberg E; de Papp AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):571-80. PubMed ID: 23337728
[TBL] [Abstract][Full Text] [Related]
7. ONO-5334, a cathepsin K inhibitor, improves bone strength by preferentially increasing cortical bone mass in ovariectomized rats.
Ochi Y; Yamada H; Mori H; Kawada N; Kayasuga R; Nakanishi Y; Tanaka M; Imagawa A; Ohmoto K; Kawabata K
J Bone Miner Metab; 2014 Nov; 32(6):645-52. PubMed ID: 24317478
[TBL] [Abstract][Full Text] [Related]
8. Cortical bone mineral density is increased by the cathepsin K inhibitor ONO-5334, which leads to a robust increase in bone strength: results from a 16-month study in ovariectomised cynomolgus monkeys.
Yamada H; Ochi Y; Mori H; Nishikawa S; Hashimoto Y; Tanaka M; Deacon S; Kawabata K
J Bone Miner Metab; 2019 Jul; 37(4):636-647. PubMed ID: 30357565
[TBL] [Abstract][Full Text] [Related]
9. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
[TBL] [Abstract][Full Text] [Related]
10. Odanacatib treatment affects trabecular and cortical bone in the femur of postmenopausal women: results of a two-year placebo-controlled trial.
Engelke K; Fuerst T; Dardzinski B; Kornak J; Ather S; Genant HK; de Papp A
J Bone Miner Res; 2015 Jan; 30(1):30-8. PubMed ID: 24898537
[TBL] [Abstract][Full Text] [Related]
11. Effects of eight-month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys.
Ochi Y; Yamada H; Mori H; Nakanishi Y; Nishikawa S; Kayasuga R; Kawada N; Kunishige A; Hashimoto Y; Tanaka M; Sugitani M; Kawabata K
Bone; 2014 Aug; 65():1-8. PubMed ID: 24784023
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.
Lewiecki EM; Keaveny TM; Kopperdahl DL; Genant HK; Engelke K; Fuerst T; Kivitz A; Davies RY; Fitzpatrick LA
J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.
Black DM; Bouxsein ML; Palermo L; McGowan JA; Newitt DC; Rosen E; Majumdar S; Rosen CJ;
J Clin Endocrinol Metab; 2008 Jun; 93(6):2166-72. PubMed ID: 18349061
[TBL] [Abstract][Full Text] [Related]
14. Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study.
Yang L; Udall WJ; McCloskey EV; Eastell R
Osteoporos Int; 2014 Jan; 25(1):251-63. PubMed ID: 23719860
[TBL] [Abstract][Full Text] [Related]
15. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
[TBL] [Abstract][Full Text] [Related]
16. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
[TBL] [Abstract][Full Text] [Related]
17. Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis.
Hasegawa C; Kastrissios H; Monteleone J; Ohno T; Umemura T; Ohyama M; Nagase S; Small M; Deacon S; Ogawa M; Ieiri I
J Clin Pharmacol; 2014 Aug; 54(8):937-48. PubMed ID: 24615681
[TBL] [Abstract][Full Text] [Related]
18. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.
Lewiecki EM; Betah D; Humbert L; Libanati C; Oates M; Shi Y; Winzenrieth R; Ferrari S; Omura F
J Bone Miner Res; 2024 May; 39(4):473-483. PubMed ID: 38477808
[TBL] [Abstract][Full Text] [Related]
19. Additive impact of alfacalcidol on bone mineral density and bone strength in alendronate treated postmenopausal women with reduced bone mass.
Felsenberg D; Bock O; Börst H; Armbrecht G; Beller G; Degner C; Stephan-Oelkers M; Schacht E; Mazor Z; Hashimoto J; Roth HJ; Martus P; Runge M
J Musculoskelet Neuronal Interact; 2011 Mar; 11(1):34-45. PubMed ID: 21364273
[TBL] [Abstract][Full Text] [Related]
20. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
